Press Release Archives


December 5, 2017
DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401 

November 20, 2017
Mechanism of Action Studies for DNAtrix’s Oncolytic Virus DNX-2401 Presented at the 2017 Society for Neuro-Oncology Annual Meeting

November 13, 2017
DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting

June 1, 2017
DNAtrix to Present Results of DNX-2401 for Recurrent Glioblastoma at the 2017 American Society of Clinical Oncology Annual Meeting

May 11, 2017
DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer

April 24, 2017
Precision Intratumoral Delivery of DNX-2401 with the Alcyone MEMS Cannula

March 30, 2017
Antitumor Immunity Triggered by DNAtrix Armed Viruses to be Presented at the 2017 Annual Meeting of the American Association for Cancer Research


November 17, 2016
DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology

November 8, 2016
DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform

November 1, 2016
DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA

August 4, 2016
DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

July 27, 2016
DNAtrix Receives European Medicines Agency PRIME Designation

July 21, 2016
DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone’s MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma

February 9, 2016
DNAtrix’s Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors


October 1, 2015
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

June 16, 2015
DNAtrix Collaborators Present Data on a Novel Oncolytic Adenovirus Expressing OX40 Ligand that Promotes Antitumor Immunity

June 8, 2015
DNAtrix Awarded Most Promising Life Science Company at 2015 Texas Life Science Forum

May 20, 2015
Alcyone Lifesciences and DNAtrix Enter Clinical Collaboration for Brain Cancer


October 14, 2014
DNAtrix Completes $20 Million Series B Financing

October 7, 2014
FDA Grants Orphan Drug Designation To DNAtrix’s Dnx-2401 For The Treatment Of Malignant Glioma

September 16, 2014
DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial

June 17, 2014
FDA Grants Fast Track Status To DNAtrix Drug DNX-2401 For Recurrent Glioblastoma

February 24, 2014
DNAtrix Awarded $10.8 Million Grant By The Cancer Prevention And Research Institute Of Texas


November 18, 2013
DNAtrix Has Been Named As One Of The “Top Advanced Therapies Projects To Watch” And Will Present At The Therapeutic Area Partnerships

November 14, 2013
DNAtrix Announces Treatment Of First Patient In Study With Recurrent Glioblastoma Using DNX-2401 And Temozolomide

June 18, 2013
DNAtrix, Inc. To Present Clinical Study Results For DNX-2401 (Delta 24-Rgd), A Conditionally Replication-Competent Adenovirus

March 26, 2013
Alcyone Lifesciences And DNAtrix, Inc., To Collaborate On Unique Delivery System To Treat Brain Tumors


October 23, 2012
DNAtrix And Vectorlogics Complete Merger Transaction